FULCRUM THERAPEUTICS, INC. Shareholders' Equity
FULCRUM THERAPEUTICS, INC. (FULC) had Shareholders' Equity of $310.70 million as of 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-09-02
- 2026-06-30: Stockholders' Equity Attributable to Parent $310.70M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $333.30M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $349.00M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $198.37M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $310.70M S-4 · filed 2026-09-02 |
| 2026-03-31 | $333.30M S-4 · filed 2026-09-02 |
| 2025-12-31 | $349.00M S-4 · filed 2026-09-02 |
| 2025-09-30 | $198.37M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $214.38M S-4 · filed 2026-09-02 |
| 2025-03-31 | $228.49M S-4 · filed 2026-09-02 |
| 2024-12-31 | $243.03M S-4 · filed 2026-09-02 |
| 2024-09-30 | $257.29M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $273.79M 10-Q · filed 2025-10-29 |
| 2024-03-31 | $213.59M 10-Q · filed 2025-10-29 |
| 2023-12-31 | $235.19M S-4 · filed 2026-09-02 |
| 2023-09-30 | $255.46M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $275.43M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $296.26M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $198.94M 10-K · filed 2025-02-25 |
| 2022-09-30 | $221.41M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $160.75M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $189.16M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $211.54M 10-K · filed 2024-02-27 |
| 2021-09-30 | $230.61M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $110.89M 10-Q · filed 2022-11-08 |
| 2021-03-31 | $127.75M 10-Q · filed 2022-11-08 |
| 2020-12-31 | $95.18M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $104.98M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $122.13M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $70.63M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $87.15M 10-K/A · filed 2023-06-26 |
| 2019-09-30 | $102.13M 10-Q · filed 2020-11-10 |
| 2019-06-30 | -$111.68M 10-Q · filed 2020-11-10 |
| 2019-03-31 | -$99.69M 10-Q · filed 2020-11-10 |
| 2018-12-31 | -$63.67M 10-K/A · filed 2023-06-23 |
| 2018-09-30 | -$55.58M 10-Q · filed 2019-11-14 |
| 2018-06-30 | -$47.15M 10-Q · filed 2019-11-14 |
| 2018-03-31 | -$39.77M 10-Q · filed 2019-11-14 |
| 2017-12-31 | -$33.27M 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |